INFECT is based on a consortium consisting of 14 international partners, including clinicians, scientists, SMEs and a patient organization, that has joined forces to employ a new strategy to advance our understanding of the pathogenesis of necrotizing soft tissue infections (NSTIs); thereby improve identification and management of patients and promote novel developments in therapeutics and diagnostics of NSTIs.

  • Karolinska Institutet, Stockholm, Sweden

    Partner 1

    Karolinska Institutet (KI) ranks as one of the world’s leading medical universities, which today account for 40 percent of all medical research in Sweden.

    Karolinska Institutet is responsible for Work Package (WP) 5, WP6 and WP9.
    Key contributors to activities are: Anna Norrby-Teglund, Professor, PhD; Mattias Svensson, PhD; and Linda Johansson, PhD.
    Professor Anna Norrby-Teglund
    Coordinator for INFECT, Team leader for Partner 1
    Professor Anna Norrby-Teglund
    Center for Infectious Medicine, Karolinska Institutet
    +46 8 585 832 97 / +46 70 792 32 56
    Karolinska University Hospital
    Huddinge F-59, S-141 86 Stockholm, Sweden
  • Rigshospitalet, Copenhagen, Denmark

    Partner 2

    Copenhagen University hospital, Rigshospitalet (RH), is a regional hospital for 1 million inhabitants and a hospital of reference for all types of highly specialized treatments in Denmark, Faeroe Islands and Greenland, totally 5.5 million inhabitants.

    Rigshospitalet is responsible for WP2.

    Key contributors to activities are: Ole Hyldegaard, MD, PhD, Erik C Jansen, MD, Dr. Med. Sci., Martin Bruun Madsen, MD, Diana Isaksen, research nurse.
    Ole Hyldegaard, MD, PhD.
    Team Leader
    Ole Hyldegaard, MD, PhD.
    Department of Anaesthesia, Head and Neck Surgery Centre
    University Hospital-Rigshospitalet
    2100 Copenhagen, Denmark
  • Karolinska University Hospital, Stockholm, Sweden

    Partner 3

    Stockholm County Council serves for the healthcare for its 2 million inhabitants in the region.

    Karolinska university Hospital is one of the Swedish partners involved in WP2.

    Key contributors to activities are: Michael Nekludov, MD.

    Michael Nekludov, MD
    Team leader
    Michael Nekludov, MD
    Karolinska University Hospital, Stockholm, Sweden
  • Blekinge Hospital, Karlskrona, Sweden

    Partner 4

    The Blekinge County Council Hospital in Karlskrona handles all trauma and acute medical care in Blekinge and is also referral centre for the Southeast region of Sweden (population 575 000) for hyperbaric medicine.

    Partner 4 is one of the Swedish partners involved in WP2.

    Key contributors to activities are: Ylva Karlsson, MD, Dag Benoni, MD.
    Team Leader
    Ylva Karlsson, MD
    Department of Anesthesiology and Intensive Care
    Blekinge County Council Hospital
    Karlskrona, S-37 185 Karlskrona, Sweden
  • Sahlgrenska University Hospital, Gothenburg, Sweden

    Partner 5

    Sahlgrenska University Hospital (SU) provides emergency and basic care for the Göteborg region, and its 700,000 inhabitants.

    Partner 5 is one of the Swedish partners involved in WP2.

    Key contributors to activities are: Per Arnell MD, Anders Rosen MD, Joakim Trogen MD, Anders Rosemar MD, PhD

    Per Arnell, MD
    Team Leader
    Per Arnell, MD
    Sahlgrenska University Hospital
    Rondvägen 5, 416 50, Gothenburg, Sweden
  • University of Bergen, Bergen, Norway

    Partner 6

    University of Bergen (UiB) is the second largest university in Norway. The Faculty of Dentistry and Medicine holds 1000 employees and the faculty is responsible for the education of medical doctors, dentists, pharmacists and nutritionist.

    Partner 6 is the Norwegian partner involved in WP2.

    Key contributors to activities are: Steinar Skrede, MD, PhD; Trond Bruun, MD, PhD,  Oddvar Oppegaard, MD, PhD, Torbjørn Nedrebø, MD, PhD, and Eivind Rath, MD.
    Steinar Skrede, MD, PhD
    Team Leader
    Steinar Skrede, MD, PhD
    Division for Infectious Diseases
    Haukeland University Hospital
    Jonas Liesvei 65, PB 1400, 5021 Bergen, Norway
  • Helmholtz-Zentrum fuer infektionsforschung GmbH, Braunschweig, Germany

    Partner 8

    HZI is a multi-disciplinary research institute and has strong collaborative links with many academic and industrial research organizations worldwide.

    Partner 8 is responsible for WP3.

    Key contributors to activities are: Dr. Dietmar Pieper, Team leader; Dr. Andreas Itzek, PhD; Dr. Patric Nitsche-Schmitz, PhD; Anshu Babbar. Dr. Gursharan S Chhatwal (deceased) made indispensable contributions in the application phase and early phases of the project.
    Prof. Dietmar Pieper
    Team Leader
    Prof. Dietmar Pieper
    Molecular Interactions and Processes
    Helmholtz-Zentrum für Infektionsforschung GmbH
    Inhoffenstraße 7, 38124 Braunschweig, Germany
  • Wageningen Universiteit, Wageningen, The Netherlands

    Partner 9

    The Wageningen University & Research (WU-ATV), is an internationally leading education and research organization, and the largest in the Netherlands focusing on life sciences (non-medical).

    Partner 9 is responsible for WP4.

    Key contributors to  activities are: Vítor Martins dos Santos, Professor; Jasper Jan Koehors, PhD; and Jesse Vandem, PhD.
    Professor Vítor Martins dos Santos
    Team Leader
    Professor Vítor Martins dos Santos
    Laboratory of Systems and Synthetic Biology
    Wageningen University
    Box 8033, 6700 EJ Wageningen, The Netherlands
  • Université Lyon, Lyon, France

    Partner 10

    Université Lyon is a multidisciplinary university specializing in both fundamental and applied research and as such it can boast more than 4415 internationally published articles and 44 patents per year.

    Partner 10 is the French partner involved in WP3.

    Key contributor to  activities are: Francois Vandenesh, Professor, MD, PhD.
    Team Leader
    Professor Francois Vandenesch
    Immunity Infection & Vaccination
    Université Claude Bernard Lyon 1
    INSERM Unit 1111, site Laennec, rue G. Paradin, 690008 Lyon
  • LifeGlimmer GmbH, Berlin, Germany

    Partner 11

    LifeGlimmer GmbH is a newly established SME with the goal of providing to the Biotechnological, Biomedical and Environmental Research Communities an efficient way to outsource Scientific Computing needs.

    Partner 11 is responsible for WP4.

    Key contributors to activities are: Vítor Martins dos Santos.
    Team Leader and the founder and CSO of Life Glimmer
    Professor Vítor Martins dos Santos
    Markelstrasse 38, Berlin 12163, Germany
  • Doreen Marsden and The Lee Spark NF Foundation, Preston, United Kingdom

    Partner 13

    The Lee Spark NF Foundation, Necrotizing Fasciitis support and education, was established in 2000.

    Partner 13 has its main role in WP8.

    Key contributor to activities is: Doreen Marsden.
    Doreen Marsden
    Team Leader
    Doreen Marsden
    The Lee Spark NF Foundation
    Moor Hey Farm
    Knowle Green, Ribchester, Preston PR3 2XE, United Kingdom
  • Tel Aviv University, Tel Aviv, Israel

    Partner 14

    Tel-Aviv University is one of largest and top research universities in Israel. The University’s Blavatnik School of Computer Science, is of international standard and acclamation.

    Partner 14 is a partner involved in WP4.

    Key contributor to activities is: Eytan Ruppin, Professor, MD, PhD.
    Professor Eytan Ruppin
    Team Leader
    Professor Eytan Ruppin
    Blavatnik School of Computer Science and School of Medicine
    Tel Aviv University
    Tel Aviv 69978, Israel
  • University of North Dakota, Grand Forks, North Dakota, United States

    Partner 15

    The University of North Dakota (UND) is the state's oldest and largest University, with more than 15,000 students and 225 fields of study. UND is a Carnegie Doctoral Research Institution with an international reputation for research and scholarship, notably in health sciences, nutrition, energy and environmental protection, aerospace, and engineering. Although UND's research is felt around the world, it plays an important role in the emergence of North Dakota as a technological and economic leader.

    Partner 15 is the American partner responsible for WP1.

    Key contributors to Partner 15 activities are: Malak Kotb, Professor, PhD.
    Professor Malak Kotb
    Team Leader
    Professor Malak Kotb
    Department of Basic Sciences, School of Medicine and Health Sciences
    University of North Dakota
    Grand Forks, North Dakota, United States
  • Cube Dx, St Valentin, Austria

    Partner 16

    Cube Dx GmbH was founded in 2015 and is located in St. Valentin (Austria). The company focuses on the development, production and distribution of multiplex tests for in-vitro diagnostics in clinical practice. Multiplex diagnostics allow for the identification in parallel of a variety of significant parameters (bacteria, gene mutations, immune response, etc.) in a single test, requiring only a minimal amount of sample material.

    Cube Dx has developed a complete and entirely new multiplex technology based on the principle of microarrays. The hybcell – the only cylindrical microarray available anywhere – delivers speedy and reliable results with minimal effort. The hyborg – a completely automated device – processes the samples fully independently and without any intervention by the user.

    The Cube Dx assay is based on compact sequencing and compact profiling, and is designed to address especially those complex diagnostic challenges where fast answers are essential. In addition to the Early Pathogen Identification Cube Dx offers tests for Companion Diagnostics (oncology) as well as Monitoring of patients suffering with severe infections or inflammation.

    Partner 16 is responsible for WP7.

    Key contributors to activities are: Christoph Reschreiter, MSc, CEO, and Bernard Ronacher, CSO
    Christoph Reschreiter
    Team Leader
    Christoph Reschreiter
    Cube Dx
    Westbahnstrasse 55, A 4300 St. Valentin, Austria